A Study to Evealuate Safety and Immunogenicity of TI-0010 SARS-CoV-2 Vaccine in Healthy Adults

This study is testing a new COVID-19 vaccine called **TI-0010** in healthy adults aged 18-59. The vaccine uses **lipid nanoparticles (LNP)**, tiny fat particles, to carry a special type of RNA called **circRNA** that targets the virus. Up to 100 people will join in 4 groups. Some will get one shot, others will get two shots 28 days apart. The shots are given in the muscle. Participants will be randomly assigned to receive either the vaccine or a **placebo**, a harmless substance that doesn't contain the vaccine, in a 4:1 ratio. Visits will occur on days 3, 7, 14, and 28 after each dose and continue for up to a year to check safety and how well the vaccine works. The study aims to see if the vaccine is safe and helps the body fight COVID-19.

• Participants will have follow-up visits up to 12 months after vaccination.
• Participants must be healthy and between 18-59 years old.
• This study is randomized, meaning some get the vaccine and some get a placebo.